Conjunctivitis: Clinical Trials

17 trials for Conjunctivitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed. 17 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 117Completed 17
Phase 24Completed 4

Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects
PRO-231, VIGAMOXI® - Ophthalmological Agent Toxicity, Bacterial Conjunctivitis
Phase 1CompletedLaboratorios Sophia S.A de C.V.372024-01-302025-06-15
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
MDI-1228_mesylate Ophthalmic Solution, Placebo - Allergic Conjunctivitis
Phase 1CompletedShanghai Medinno Pharmaceutical Technology Co., Ltd.402023-10-062024-07-09
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
INV-102, Vehicle - Dry Eye Disease
Phase 1 / Phase 2CompletedInvirsa, Inc.842022-08-302026-09-18
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
Cyclosporine 0.05% eye drops, Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% - Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops
Phase 1CompletedSecond Affiliated Hospital of Nanchang University482020-07-012022-04-29
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
CTH522-CAF01 IM, CTH522-CAF09b IM, CTH522 ID - Trachoma
Phase 1CompletedStatens Serum Institut652020-02-172024-08-22
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
PP-001, Placebo - Keratoconjunctivitis, Ocular Surface Disease
Phase 1CompletedPanoptes Pharma GmbH452018-11-202024-01-12
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Conjunctivitis, Allergic
Phase 1 / Phase 2CompletedAldeyra Therapeutics, Inc.702018-10-022025-02-24
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis
Phase 1 / Phase 2CompletedAldeyra Therapeutics, Inc.522018-09-082025-04-08
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
AK002 - Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis
Phase 1CompletedAllakos Inc.302018-02-262019-08-29
Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects
PRO-174, Sophixín Ofteno® - Conjunctivitis, Conjunctivitis, Bacterial
Phase 1CompletedLaboratorios Sophia S.A de C.V.302018-01-252019-10-25
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
XmAb7195, Placebo - Allergic Rhinitis, Allergic Conjunctivitis
Phase 1CompletedXencor, Inc.722014-05-012017-01-24
Safety and Efficacy of PG101 for Dry Eye Syndrome
PG101 - Dry Eye Syndrome
Phase 1 / Phase 2CompletedRhodes Pharmaceuticals, L.P.722013-12-012014-03-05
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0% - Keratoconjunctivitis Sicca
Phase 1CompletedRigel Pharmaceuticals362012-11-012014-08-04
Safety and Comfort of AL-4943A Ophthalmic Solution
Olopatadine hydrochloride ophthalmic solution, 0.7%, Olopatadine hydrochloride ophthalmic solution vehicle, Ketotifen fumarate ophthalmic solution, 0.025% - Allergic Conjunctivitis
Phase 1CompletedAlcon Research502011-04-012015-03-03
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
voclosporin ophthalmic solution - Keratoconjunctivitis Sicca
Phase 1CompletedLux Biosciences, Inc.352009-02-012012-06-22
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
300 IR grass pollen allergen extract tablet, Placebo tablet - Seasonal Allergic Rhinitis
Phase 1CompletedStallergenes Greer892007-09-012016-05-23
Systemic Pharmacokinetics of BOL-303224-A
BOL-303224-A - Conjunctivitis, Bacterial
Phase 1CompletedBausch & Lomb Incorporated242006-10-012011-12-09

Narrower conditions

Conjunctivitis, Allergic (7)  ·  Keratoconjunctivitis Sicca (4)  ·  Conjunctivitis, Bacterial (3)  ·  Dry Eye Syndromes (2)  ·  Chlamydia Infections (1)  ·  Dermatitis, Atopic (1)  ·  Keratoconjunctivitis (1)  ·  Rhinitis (1)  ·  Rhinitis, Allergic (1)  ·  Rhinitis, Allergic, Seasonal (1)  ·  Trachoma (1)

Broader conditions

Conjunctival Diseases (17)  ·  Eye Diseases (17)  ·  Hypersensitivity (8)  ·  Hypersensitivity, Immediate (8)  ·  Immune System Diseases (8)  ·  Corneal Diseases (6)  ·  Infections (5)  ·  Keratitis (5)  ·  Bacterial Infections (4)  ·  Bacterial Infections and Mycoses (4)  ·  Eye Infections (4)  ·  Eye Infections, Bacterial (4)  ·  Keratoconjunctivitis (4)  ·  Lacrimal Apparatus Diseases (4)

Interventions

AK002 (1)  ·  Cyclosporine (1)  ·  Gels (1)  ·  Loteprednol Etabonate (1)  ·  Moxifloxacin (1)  ·  Olopatadine Hydrochloride (1)  ·  Ophthalmic Solutions (1)  ·  Sodium Chloride (1)  ·  Sublingual Immunotherapy (1)  ·  besifloxacin (1)  ·  ketotifen fumarate ophthalmic solution (1)

Sponsors

Aldeyra Therapeutics, Inc. (2)  ·  Laboratorios Sophia S.A de C.V. (2)  ·  Alcon Research (1)  ·  Allakos Inc. (1)  ·  Bausch & Lomb Incorporated (1)  ·  Invirsa, Inc. (1)  ·  Lux Biosciences, Inc. (1)  ·  Panoptes Pharma GmbH (1)  ·  Rhodes Pharmaceuticals, L.P. (1)  ·  Rigel Pharmaceuticals (1)  ·  Second Affiliated Hospital of Nanchang University (1)  ·  Shanghai Medinno Pharmaceutical Technology Co., Ltd. (1)  ·  Stallergenes Greer (1)  ·  Statens Serum Institut (1)  ·  Xencor, Inc. (1)

Countries

United States (8)  ·  Austria (2)  ·  Mexico (2)  ·  Australia (1)  ·  Canada (1)  ·  China (1)  ·  United Kingdom (1)

Top investigators

Abhijit Narvekar, MS, MBBS (1)  ·  Alejandra Sanchez-Rios, MD (1)  ·  Alvaro Borges, MD (1)  ·  Gail Torkildsen, M.D. (1)  ·  Gail Torkildsen, MD (1)  ·  Katrina Pollock, MD (1)  ·  Liang Lu, PhD (1)  ·  Lina S Stoey, MPH (1)  ·  Pernille N Tingskov, BS (1)  ·  Quan D Nguyen, MD, MSc (1)  ·  Rebecca B Dohn, Pharm (1)  ·  Robert Shalwitz, MD (1)  ·  Ronald Goldwater, MD (1)

Results publications

PMID 19647862, PMID 23181790, PMID 24261946, PMID 34707360, PMID 35585427, PMID 38615673